GlassScriptPhysician profile
Samantha Mayerhoff
NPI 1841536828
$1,475.43
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $884 · 2022: $591.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $247.31 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $231.02 | 2021-2022 | |
| Lilly USA, LLC | $127.84 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $101.63 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.88 | 2021-2022 | |
| Amgen INC. | $88.86 | 2021-2022 | |
| Novo Nordisk INC | $82.03 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $78.48 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $68.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.28 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.21 | 2022 | |
| Janssen Pharmaceuticals, INC | $49.32 | 2021 | |
| Glaxosmithkline, LLC. | $39.13 | 2021 | |
| Eisai INC. | $29.32 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.99 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $20.72 | 2022 | |
| Daiichi Sankyo INC. | $18.93 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.68 | 2021 | |
| Mylan Specialty L.P. | $15.29 | 2022 | |
| Pfizer INC. | $14.99 | 2022 | |
| Currax Pharmaceuticals LLC | $13.17 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.34 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Mayerhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.